Exhibit 99.1

Kamada Reports Second Quarter and First Six Months of 2020 Financial Results, Recent Corporate
Achievements and Strong Cash Position

● Second Quarter Revenues were $33.1 million, Compared to $35.3 million in 2019, First Half 2020 Revenues were $66.4 million, up 7% from 2019

● Net Income for the Second Quarter and for the First Half of 2020 was $3.5 million and $8.7 million, Respectively, Compared to $6.1 million and $11.1 million in 2019 Respectively

● Significant Progress Achieved in Development of a Plasma-Derived Immunoglobulin (IgG) Product as a Potential Treatment for Coronavirus Disease (COVID-19)

● Approximately $100 million of Available Net Cash as of June 30, 2020

● Exploring Business Development Initiatives  Targeted to Mitigate the Effect of the Planned Transition of GLASSIA® Manufacturing to Takeda During 2021

● Company Reiterates Full-Year 2020 Total Revenue Guidance of $132 Million to $137 Million

REHOVOT, Israel – August 12, 2020 -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today announced financial results for the three and six months ended June 30, 2020.

“Kamada presented solid financial and operational performance during the first six months of 2020,” said Amir London, Kamada’s Chief Executive Officer. “While the global COVID-19 pandemic persists, we generated total revenues of $66.4 million during the first half of the year, representing an increase of 7% year-over-year. Importantly, our manufacturing plant continues to be operational and we do not anticipate any meaningful changes in the foreseeable future due to COVID-19 pandemic. Based on our results in the first six months of 2020 and our current outlook for the remainder of the year, we are reiterating our guidance of total revenues of between $132 million and $137 million for full-year 2020.”

“We continue to expeditiously advance the development of our plasma-derived immunoglobulin (IgG) product as a potential treatment for coronavirus disease (COVID-19),” continued Mr. London. “We have completed manufacturing of the initial batches of our product and earlier this week we announced first-patient-in our Phase 1/2 open label clinical trial in Israel. We are also working with the support of our partner, Kedrion Biopharma, toward obtaining FDA’s acceptance of the proposed clinical development program and we expect to hold a pre-IND meeting with the FDA during this quarter.”

“We are intensively exploring business development opportunities to mitigate the effects of the planned transition of GLASSIA^® manufacturing to Takeda during 2021. I am optimistic that these opportunities, funded by our strong cash position, along with our organic commercial growth, our investigational COVID- 19 IgG product, the expected future royalty payments from Takeda together with the contract manufacturing of an FDA approved and commercialized specialty IgG product will contribute to our future growth” concluded Mr. London.

Financial Highlights for the Three Months Ended June 30, 2020

● Total revenues were $33.1 million in the second quarter of 2020, a 6% decrease from the $35.3 million recorded in the second quarter of 2019

o Proprietary Products segment revenues in the second quarter of 2020 were $22.6 million, a 17% decrease from the second quarter of 2019. The decrease this quarter is due to expediting shipments in the first quarter in anticipation of global transportation instability in the wake of the COVID-19.  Overall six months revenues from the Proprietary Products segment are up 1%.

o Distribution segment revenues were $10.5 million in the second quarter of 2020, a 31% increase from the second quarter of 2019

1

● Gross profit was $11.1 million in the second quarter of 2020, compared to $13.6 million reported in the second quarter of 2019

o Proprietary Product segment gross margins in the second quarter were 43%, down three percentage points from the second quarter of 2019, in line with previous guidance expecting three to five percentage points’ annual decrease which is attributable to a change in sales product mix and reduced plant utilization.

● Operating expenses, including Research and Development, Sales and Marketing, General and Administrative, and Other expenses, totaled $7.1 million in the second quarter of 2020, as compared to $7.2 million in the second quarter of 2019

o 2020 Research and Development expenses guidance was for an expected 20-25% annual increase. Given COVID-19-related delays we currently expect a 15-17% increase for full year 2020 as compared to 2019.

● Net income was $3.5 million, or $0.08 per share, in the second quarter of 2020, as compared to net income of $6.1 million, or $0.15 per share, in the second quarter of 2019

● Adjusted EBITDA, as detailed in the tables below, was $5.5 million in the second quarter of 2020, as compared to $7.8 million in the second quarter of 2019

● Cash provided by operating activities was $10.7 million in the second quarter of 2020, as compared to cash provided by operating activities of $6.8 million in the second quarter of 2019

Financial Highlights for the Six Months Ended June 30, 2020

● Total revenues were $66.4 million in the first six months of 2020, a 7% increase from the $62.1 million recorded in the first six months of 2019

o Revenues from the Proprietary Products segment for the first six months of 2020 were $47.9 million, a 1% increase from the $47.7 million reported in the first six months of 2019

o Revenues from the Distribution segment were $18.4 million in the first six months 2020, a 28% increase from the $14.4 million recorded in the first six months of 2019

● Gross profit was $22.6 million in the first six months 2020, a 9% decrease from the $24.8 million reported in the first six months 2019, primarily due to changes in the product mix

● Operating expenses, including Research and Development, Sales & Marketing, General and Administrative, and Other expenses, totaled $13.7 million in the first six months 2020, as compared to $13.2 million in the first six months 2019

● Net income was $8.7 million, or $0.20 per share, in the first six months of 2020, as compared to net income of $11.1 million, or $0.27 per share, in the first six months of 2019

● Adjusted EBITDA, as detailed in the tables below, was $11.8 million in the first six months of 2020, as compared to $14.5 million in the first six months of 2019

● Cash provided by operating activities was $8.7 million in the first six months of 2020, as compared to cash provided by operating activities of $12.8 million in the first six months of 2019

Balance Sheet Highlights

As of June 30, 2020, the Company had cash, cash equivalents, and short-term investments of $104.7 million, as compared to $73.9 million at December 31, 2019.

Conference Call

Kamada management will host an investment community conference call on Wednesday, August 12, 2020, at 8:30am Eastern Time to discuss these results and answer questions. Shareholders and other interested parties may participate in the conference call by dialing 855-327-6837 (from within the U.S.), 1-809-458-327 (from Israel), or 631-891-4304 (International) and entering the conference identification number: 10010379. The call will also be webcast live on the Internet on the Company’s website at www.kamada.com.

2

About Kamada

Kamada Ltd. (“the Company”) is a commercial stage plasma-derived biopharmaceutical company focused on orphan indications, with an existing marketed product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived immune globulins. The Company’s flagship product is GLASSIA®, the first liquid, ready-to-use, intravenous plasma-derived AAT product approved by the U.S. FDA. The Company markets GLASSIA in the U.S. through a strategic partnership with Takeda Pharmaceuticals Company Limited and in other countries through local distributors. The Company’s second leading product is KamRab®, a rabies immune globulin (Human) for post-exposure prophylaxis against rabies infection. KamRab is FDA approved and is being marketed in the U.S. under the brand name KEDRAB® through a strategic partnership with Kedrion S.p.A. In addition to Glassia and KEDRAB, the Company has a product line of four other plasma-derived pharmaceutical products administered by injection or infusion, that are marketed through distributors in more than 15 countries, including Israel, Russia, Brazil, India and other countries in Latin America and Asia. The Company has late-stage products in development, including an inhaled formulation of AAT for the treatment of AAT deficiency. In addition, the Company’s intravenous AAT is in development for other indications, such as GvHD and prevention of lung transplant rejection, and during 2020, the Company initiated the development of a plasma derived immunoglobulin (IgG) product as a potential treatment for coronavirus disease (COVID-19). The Company leverages its expertise and presence in the plasma-derived protein therapeutics market by distributing more than 20 complementary products in Israel that are manufactured by third parties. FIMI Opportunity Fund, the leading private equity investor in Israel, is the Company’s lead shareholder, beneficially owning approximately 21% of the outstanding ordinary shares.

Cautionary Note Regarding Forward-Looking Statements

This release includes forward-looking statements within the meaning of Section 21E of the U.S. Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, including statements regarding 1) Total revenues to be in the range of $132 million to $137 million for fiscal 2020; 2) not anticipating meaningful changes in operations in the foreseeable future due to COVID-19 pandemic; 3) actions taken to mitigate the effect of the planned transition of GLASSIA manufacturing to Takeda during 2021; 4) optimism that business development opportunities, funded by our strong cash position, along with our organic commercial growth, our investigational COVID- 19 IgG product, the expected future royalty payments from Takeda together with the contract manufacturing of an FDA approved and commercialized specialty IgG product will contribute to our future growth; 5) developments relating FDA’s acceptance of the proposed clinical development program and clearance of Kamada’s IND relating to its plasma-derived immunoglobulin (IgG) product as a potential treatment for coronavirus disease (COVID-19) following the pre-Investigational New Drug (IND) meeting with the FDA expected to take place in the third quarter of 2020; 6) guidance of an expected annual three to five percentage points decrease in the Proprietary Product segment gross margin which is attributable to a change in sales product mix and reduced plant utilization; and 7) previously expected increase of 20-25% in Research and Development expenses for 2020 in comparison to 2019 will not materialize mainly related to COVID-19 related delays in research projects and current expectation of an approximately 15-17% increase in Research and Development expenses in full year 2020 as compared to 2019. Forward-looking statements are based on Kamada’s current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to, the continued evolvement of the COVID-19 pandemic, its scope, effect and duration, availability of sufficient raw materials required to maintain manufacturing plans, the effects of the COVID-19 pandemic and related government mandates on the availability of adequate levels of work-force required to maintain manufacturing plans, disruption to the supply chain due to COVID-19 pandemic, continuation of inbound and outbound international delivery routes, ability to offset significant revenue loss associated with GLASSIA manufacturing transitioning to Takeda, continued demand for Kamada’s products, including GLASSIA and KEDRAB, in the U.S. market and its Distribution segment related products in Israel, financial conditions of the Company’s customer, suppliers and services providers, ability to obtain regulatory approval for clinical trials of the plasma-derived hyperimmune IgG product for COVID-19, ability to continue enrollment of the pivotal Phase 3 InnovAATe clinical trial, unexpected results of clinical studies and on-going compassionate-use treatments, Kamada’s ability to manage operating expenses, additional competition in the markets that Kamada competes, regulatory delays, prevailing market conditions and the impact of general economic, industry or political conditions in the U.S., Israel or otherwise. The forward-looking statements made herein speak only as of the date of this announcement and Kamada undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.

CONTACTS:

Chaime Orlev

Chief Financial Officer

IR@kamada.com

Bob Yedid

LifeSci Advisors, LLC

646-597-6989

Bob@LifeSciAdvisors.com

3

CONSOLIDATED CONDENSED BALANCE SHEETS

	As of June 30,						As of December 31,
	2020			2019			2019
	Unaudited						Audited
	U.S Dollars in thousands
Assets
Current Assets
Cash and cash equivalents	$	57,399		$	23,835		$	42,662
Short-term investments		47,272			38,122			31,245
Trade receivables, net		19,823			25,497			23,210
Other accounts  receivables		2,980			3,292			3,272
Inventories		47,646			35,501			43,173
Total Current Assets		175,120			126,247			143,562
Non-Current Assets
Property, plant and equipment, net		24,574			24,478			24,550
Right-of-use-assets		3,796			3,946			4,022
Other long term assets		1,058			174			352
Contract asset		911			-			-
Deferred taxes		632			1,644			1,311
Total Non-Current Assets		30,971			30,242			30,235
Total Assets	$	206,091		$	156,489		$	173,797
Liabilities
Current Liabilities
Current maturities of bank loans	$	431		$	480		$	489
Current maturities of lease liabilities		990			960			1,020
Trade payables		22,760			19,879			24,830
Other accounts payables		5,497			4,876			5,811
Deferred revenues		589			461			589
Total Current Liabilities		30,267			26,656			32,739
Non-Current Liabilities
Bank loans		63			482			257
Lease liabilities		3,704			3,988			3,981
Deferred revenues		1,025			542			232
Employee benefit liabilities, net		1,267			818			1,269
Total Non-Current Liabilities		6,059			5,830			5,739
Shareholder’s Equity
Ordinary shares		11,662			10,418			10,425
Additional paid in capital		207,731			179,471			180,819
Capital reserve due to translation to presentation currency		(3,490	)		(3,490	)		(3,490	)
Capital reserve from hedges		411			8			8
Capital reserve from financial assets measured at fair value through other comprehensive income		-			187			145
Capital reserve from share-based payments		6,204			9,663			8,844
Capital reserve from employee benefits		(356	)		4			(359	)
Accumulated deficit		(52,397	)		(72,258	)		(61,073	)
Total Shareholder’s Equity		169,765			124,003			135,319
Total Liabilities and Shareholder’s Equity	$	206,091		$	156,489		$	173,797

4

CONSOLIDated condensed statements of comprehensive income

	Six months period ended						Three months period ended						Year ended
	June 30,						June 30,						December 31,
	2020			2019			2020			2019			2019
	Unaudited						Unaudited						Audited
	U.S Dollars In thousands
Revenues from proprietary products	$	47,942		$	47,662		$	22,625		$	27,281		$	97,696
Revenues from distribution		18,437			14,388			10,464			7,972			29,491
Total revenues		66,379			62,050			33,089			35,253			127,187
Cost of revenues from proprietary products		27,881			25,178			12,934			14,688			52,425
Cost of revenues from distribution		15,932			12,088			9,040			6,965			25,025
Total cost of revenues		43,813			37,266			21,974			21,653			77,450
Gross profit		22,566			24,784			11,115			13,600			49,737
Research and development expenses		6,970			6,253			3,623			3,487			13,059
Selling and marketing expenses		2,118			2,280			1,178			1,188			4,370
General and administrative expenses		4,619			4,621			2,307			2,527			9,194
Other expenses		34			28			32			5			330
Operating income		8,825			11,602			3,975			6,393			22,784
Financial income		615			559			298			274			1,146
Income (expense) in respect of securities measured at fair value, net *		102			(58	)		-			(7	)		(5	)
Income (expenses) in respect of currency exchange differences and derivatives instruments, net		65			(528	)		(367	)		(215	)		(651	)
Financial expenses		(135	)		(149	)		(58	)		(72	)		(293	)
Income before tax on income		9,472			11,426			3,848			6,373			22,981
Taxes on income		796			360			390			230			730
Net Income	$	8,676		$	11,066		$	3,458		$	6,143		$	22,251
Other Comprehensive Income (loss):
Amounts that will be or that have been reclassified to profit or loss when specific conditions are met
Gain (loss) from securities measured at fair value through other comprehensive income		(188	)		198			-			90			143
Gain (loss) on cash flow hedges		441			71			200			(3	)		92
Net amounts transferred to the statement of profit or loss for cash flow hedges		(7	)		(2	)		(41	)		-			(23	)
Items that will not be reclassified to profit or loss in subsequent periods:
Remeasurement gain (loss) from defined benefit plan		-			-			-			-			(388	)
Tax effect		15			(49	)		(12	)		(21	)		(11	)
Total comprehensive income	$	8,937		$	11,284		$	3,605		$	6,209		$	22,064
Earnings per share attributable to equity holders of the Company:
Basic net earnings per share	$	0.20		$	0.27		$	0.08		$	0.15		$	0.55
Diluted net earnings per share	$	0.20		$	0.27		$	0.08		$	0.15		$	0.55

5

CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS

	Six months period Ended						Three months period Ended						Year Ended
	June, 30						June, 30						December 31,
	2020			2019			2020			2019			2019
	Unaudited												Audited
	U.S Dollars In thousands
Cash Flows from Operating Activities
Net income	$	8,676		$	11,066		$	3,458		$	6,143		$	22,251
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Adjustments to the profit or loss items:
Depreciation and impairment		2,380			2,251			1,188			1,124			4,519
Financial expenses (income), net		(647	)		176			127			20			(197	)
Cost of share-based payment		588			634			330			319			1,163
Taxes on income		796			360			390			230			730
Loss (gain) from sale of property and equipment		(6	)		(2	)		(6	)		4			(2	)
Change in employee benefit liabilities, net		(2	)		31			16			(5	)		94
		3,109			3,450			2,045			1,692			6,307
Changes in asset and liability items:
Decrease (increase) in trade receivables, net		3,416			2,602			6,432			(2,125	)		5,117
Decrease (increase) in other accounts receivables		741			249			(772	)		118			(214	)
Increase in inventories		(4,473	)		(6,185	)		(5,859	)		(3,793	)		(13,857	)
Decrease (increase) in Contract asset and deferred expenses		(911	)		(272	)		(490	)		(26	)		399
Increase (decrease) in trade payables		(2,719	)		1,927			4,497			4,295			6,259
Increase (decrease) in other accounts payables		(314	)		(53	)		866			457			863
Decrease in deferred revenues		793			(126	)		396			(63	)		(283	)
		(3,467	)		(1,858	)		5,070			(1,137	)		(1,716	)
Cash received (paid) during the period for:
Interest paid		(107	)		(124	)		(52	)		(61	)		(243	)
Interest received		601			300			150			128			1,106
Taxes paid		(74	)		(16	)		(13	)		(8	)		(134	)
		420			160			85			59			729
Net cash provided by operating activities	$	8,738		$	12,818		$	10,658		$	6,757		$	27,571

6

CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS

	Six months period Ended						Three months period Ended						Year Ended
	June, 30						June, 30						December 31,
	2020			2019			2020			2019			2019
	Unaudited												Audited
	U.S Dollars In thousands
Cash Flows from Investing Activities
Proceeds of investment in short term investments, net	$	(15,646	)	$	(5,128	)	$	-		$	(4,070	)	$	1,727
Purchase of property and equipment and intangible assets		(1,901	)		(757	)		(1,005	)		(453	)		(2,300	)
Proceeds from sale of property and equipment		6			9			6			3			9
Net cash used in investing activities		(17,541	)		(5,876	)		(999	)		(4,520	)		(564	)
Cash Flows from Financing Activities
Proceeds from exercise of share base payments		20			9			15			6			16
Repayment of lease liabilities		(540	)		(529	)		(262	)		(266	)		(1,070	)
Repayment of long-term loans		(246	)		(232	)		(123	)		(117	)		(476	)
Proceeds from issuance of ordinary shares, net		24,894			-			-			-			-
Net cash provided by (used in) financing activities		24,128			(752	)		(370	)		(377	)		(1,530	)
Exchange differences on balances of cash and cash equivalent		(588	)		(448	)		(1,178	)		(62	)		(908	)
Increase in cash and cash equivalents		14,737			5,742			8,111			1,798			24,569
Cash and cash equivalents at the beginning of the period		42,662			18,093			49,288			22,037			18,093
Cash and cash equivalents at the end of the period	$	57,399		$	23,835		$	57,399		$	23,835		$	42,662
Significant non-cash transactions
Right-of-use asset recognized with corresponding lease liability	$	345		$	4,548		$	287		$	117		$	5,035
Purchase of property and equipment	$	722		$	385		$	722		$	385		$	992

7

Adjusted EBITDA
	Six months period ended					Three months period ended				Year ended
	June 30,					June 30,				December 31,
	2020			2019		2020		2019		2019
		In thousands
Net income	$	8,676		$	11,066	$	3,458	$	6,143	$	22,251
Taxes on income		796			360		390		230		730
Financial expense (income), net		(647	)		176		127		20		(197	)
Depreciation and amortization expense		2,380			2,251		1,188		1,124		4,519
Non-cash share-based compensation expenses		588			634		330		319		1,163
Adjusted EBITDA	$	11,793		$	14,487	$	5,493	$	7,836	$	28,466

Adjusted net income
	Six months period ended				Three months period ended				Year ended
	June 30,				June 30,				December 31,
	2020		2019		2020		2019		2019
		In thousands
Net income	$	8,676	$	11,066	$	3,458	$	6,143	$	22,251
Share-based compensation charges		588		634		330		319		1,163
Adjusted net income	$	9,264	$	11,700	$	3,788	$	6,462	$	23,414

8